Boston Scientific (NYSE:BSX) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Boston Scientific (NYSE:BSX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Boston Scientific’s Q2 2025 earnings at $0.73 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, FY2025 earnings at $2.93 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS, FY2027 earnings at $3.88 EPS, FY2028 earnings at $4.32 EPS and FY2029 earnings at $4.79 EPS.

BSX has been the topic of a number of other reports. Citigroup reiterated a “buy” rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Evercore ISI upped their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Argus set a $130.00 price target on Boston Scientific in a research note on Tuesday, February 18th. Royal Bank Of Canada raised their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. Finally, Morgan Stanley increased their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, May 16th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $116.09.

Boston Scientific Stock Performance

NYSE:BSX opened at $101.36 on Monday. The firm’s 50-day moving average is $101.44 and its 200-day moving average is $98.91. The company has a market cap of $149.96 billion, a price-to-earnings ratio of 73.99, a PEG ratio of 2.63 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. Boston Scientific has a 52-week low of $71.88 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the previous year, the business earned $0.56 earnings per share. The company’s quarterly revenue was up 20.9% on a year-over-year basis. Equities research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 164,443 shares of the business’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now directly owns 1,535,706 shares in the company, valued at $157,379,150.88. The trade was a 9.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm’s stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president now directly owns 178,342 shares in the company, valued at approximately $18,347,824.96. This represents a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 411,970 shares of company stock valued at $42,406,693 in the last quarter. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Large investors have recently made changes to their positions in the company. Colonial Trust Co SC raised its stake in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC bought a new position in Boston Scientific in the 4th quarter valued at approximately $26,000. 1248 Management LLC acquired a new stake in Boston Scientific during the 1st quarter worth approximately $26,000. Finally, Y.D. More Investments Ltd bought a new stake in Boston Scientific during the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.